

# The VA Opioid Safety Initiative – how did we get here and what is ahead?

#### Friedhelm Sandbrink MD

Acting National Program Director for Pain Management, Specialty Care Services
Director Pain Management, Washington DC VA Medical Center

#### Von Moore, PharmD

VA Pharmacy Benefits Management Services (PBM) and Center for Medication Safety (VA MedSAFE)

No relevant financial relationships or conflicts of interest. No discussion of off label use of drugs or devices.

The presentation is the personal opinion of the presenters and does not reflect the official views of the Department of Veterans Affairs or any other Federal Agency.



# Objectives/Overview

- Introduction
- Risk factors for Overdose/Suicide and OUD
- Opioid Safety Initiative in VHA
- Federal Initiatives and the Comprehensive Addiction and Recovery Act (2016)
- OSI components:
  - Opioid Safety Initiative/Opioid Risk Mitigation
  - Dashboards
  - VA-DoD Clinical Practice Guideline
  - Provider Education
  - Complementary and integrative health (CIH)
  - Stepped Care Model and Pain Management Teams
- OSI patient care reviews
- Pain, MH and SUD cooperation



# Pain Management and Opioid Safety as Foundational Services in VHA

- Chronic pain is more common in Veterans than in the non-veteran US population, more often severe and in the context of comorbidities.
- Pain severity and co-concurrence with mental health comorbidities result in high impact pain (i.e. associated with substantial restriction of participation in work, social, and self-care activities).
- Behavioral Health Autopsy report (2015) "The most frequently identified risk factor among Veterans who died by suicide was pain".
- Pain, medical and/or mental comorbidities are often related to military service and/or require Veteran-specific expertise.
- Veterans are at high risk for harms from opioid medication.
- Integrated care: systematic coordination of medical, psychological and social aspects of health care is required for high quality pain care.

VHA: Pain Management and Opioid Safety is included in the list of "Foundational Services"



### Patient Robert B.\*


# 32 y/o OEF/OIF Veteran recently transitioned to care in VHA CC of low back pain

\* Case study includes minor modifications to protect anonymity

- Pain condition: low back pain with axial and radicular features, with significant degenerative disk disease on his spine by MRI; not surgical candidate.
- Comorbidities: PTSD (severe), TBI (mild)
- No illicit drug use
- Longstanding high dose opioid therapy that was already initiated during active military service, with Morphine SR 45 mg TID.
- At VA: Morphine dosage was gradually reduced over several months to 30 mg TID and then kept stable per patient request.
- Patient is on time with refills, not early. UDS as expected.
- The day after one of his opioid medication renewals, he was found by his father unresponsive in his bed at home.
- Review of chart: about 2 weeks prior to his last opioid renewal, he was seen by his Mental Health provider where he complained about poor sleep and also reported worsened anxiety. He had received a new diazepam prescription at that time.
- Accidental or suicidal overdose of multiple CNS depressant medications/substances.



# Prescription Opioid Sales, Opioid Overdose Deaths and Opioid Use Disorder



SOURCES: National Vital Statistics System, 1999-2008; Automation of Reports and Consolidated Orders System (ARCOS) of the Drug Enforcement Administration (DEA), 1999-2010; Treatment Episode Data Set, 1999-2009; <a href="http://www.cdc.gov/vitalsigns/painkilleroverdoses/infographic.html">http://www.cdc.gov/vitalsigns/painkilleroverdoses/infographic.html</a>



# The Opioid Overdose Challenge in VHA

Accidental Poisoning Mortality Among Patients in the Department of Veterans Affairs Health System.

Bohnert, Ilgen, Galea et al. Med Care 2011


- Study of all 5,567,621 Veterans in VHA in FY 2004/05 alive at start of FY 2005
- 1,013 died of accidental poisoning in FY 2005.

	U.S.	2005	V.H.A. FY2005			
Gender/ Age Group	Accidental Poisonings	Crude Rate per 100,000 person-years	Accidental Poisonings	Crude Rate per 100,000 person-years	Standardized Mortality Ratio <sup>b</sup>	95% Confidence Interval
Males	15,679	14.51	960	20.62	1.98	1.85, 2.10
18-29 yrs	3,390	13.45	28	21.86	1.62	1.02, 2.23
30-64 yrs	11,826	17.53	841	36.81	2.10	1.96, 2.24
65+ yrs	463	3.01	91	4.06	1.35	1.07, 1.63
Females	7,647	6.68	53	11.82	1.61	1.18, 2.04
18-29 yrs	1,024	4.28	1	1.70	n/a	n/a
30-64 yrs	6,155	8.91	50	15.34	1.72	1.24, 2.20
65+ yrs	468	2.19	2	3.14	n/a	n/a
Total	23,326	10.49	1,013	19.85	1.96	1.83, 2.08

- Opioid medication 32.3% (incl. methadone 13.8%), cocaine 23.3%, other/unspecified narcotics 8.5%,
   antidepressants 8.1%, benzos 7.55, synthetic heroin 6.3%, psychostimulants 4.4%, synthetic narcotics 4.3%
- "VHA patients had nearly twice the rate of fatal accidental poisoning compared with adults in the general US population."



### Overdose Deaths Involving Opioids 2016



64,070 Americans died from drug overdoses in 2016, including illicit drugs and prescription opioids – nearly double in a decade. For comparison: cocaine: 10,619; methamphetamine 7,663

https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates



# Opioid Use Disorder (OUD) Epidemic

- Anyone who takes prescription opioids can become addicted to them.
- In 2014, nearly two million Americans either abused or were dependent on prescription opioid pain relievers.
- 25-41% of patients on prescription opioids meet criteria for OUD (DSM-5).
- Heroin-related deaths more than tripled between 2010 and 2014.
- Among new heroin users entering treatment programs, ¾ report initiating misuse with prescription opioids.



Why America Can't Kick Its Painkiller Problem, TIME Magazine June 4, 2015

CDC



### Risk Factors for Overdose and OUD

### Risk factors are related to:

- Opioid prescribing
- Interaction with other medication/drugs
- Medical comorbidities
- Mental health comorbidities


"Opioid dosage was the factor most consistently analyzed and also associated with increased risk of overdose. Other risk factors include concurrent use of sedative hypnotics, use of extended-release/long-acting opioids, and the presence of substance use and other mental health disorder comorbidities."

Park et al. J Addict Med 2016

Review of 15 articles published between 2007 and 2015 that examined risk factors for fatal and nonfatal overdose in patients receiving opioid analysis.



## Higher Dosage Increases Risks from Opioids



### <u>Hazard Ratios(HR):</u>

#### **Mortality** (all causes):

**HR 1.64** for LA opioids

#### **Overdose deaths** (unintentional)

**HR 7.18-8.9** for MME > 100 mg/d

### Opioid use disorder

on long-term opioids (> 90 d)

**HR 15** for 1-36 mg/d MME

HR 29 for 36-120 mg/d MME

**HR 122** for > 120 mg/d MME

Edlund et al 2014



# Dosage and Risk of Overdose from Opioids

### "Association Between Opioid Prescribing Patterns and Opioid Overdose-

Related Deaths"

Risk of Opioid Overdose Death, HR (95% CI)

Chronic Pain

(n = 111759)

0.63 (0.50-0.80)

Maximum prescribed daily opioid dose, mg/d 1-<20 1 [Reference] 20-<50 1.88 (1.33-2.67) 50-<100 4.63 (3.18-6.74) ≥100 7.18 (4.85-10.65)

Pain-related diagnoses Cancer	0.99 (0.72-1.36)
Chronic bodily pains	0.69 (0.35-1.33)
Headache	1.02 (0.74-1.41)
Neuropathy	0.64 (0.38-1.08)
Injuries and acute pain	1.37 (1.08-1.74)
Other diagnoses	

Substance use disorders 2.53 (1.99-3.22) Other psychiatric disorders 1.87 (1.48-2.38)

COPD, CVD, and sleep apnea

Bohnert et al, JAMA 2011

- Case-cohort study
- All FY2004/05 VHA pts who died of opioid overdose by FY2008
  - Random sample for comparison

**Opioid OD deaths:** 

**Total 750 cases** 

296 cases

498 cases



# Dosage and Risk of Overdose from Opioids

### "Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths" Bohnert et al, JAMA 2011

Table 2. Unadjusted Rate of Prescription Opioid Overdose Death by Opioid Dose and Fill Type					
	Overdose Deaths, No.	Person- Months	Overdose Death Rate per 1000 Person-Months (95% CI)		
Patients With Chronic Noncancer Pain Diagnoses					
Maximum prescribed daily opioid dose, mg/d 0	243	2729022.7	0.09 (0.08-0.10)		
1-<20	44	395 205.0	0.11 (0.08-0.15)		
20-<50	108	458 296.2	0.24 (0.19-0.28)		
50-<100	86	129 491.6	0.66 (0.53-0.82)		
≥100	<del></del>	100 479.3	1.24 (1.04-1.48)		
Fill types					
Regularly scheduled only	115	323 304.7	0.36 (0.29-0.43)		
As needed only	152	672 276.0	0.23 (0.19-0.27)		
Simultaneous as needed and regularly scheduled	96	87891.5	1.09 (0.88-1.33)		


- Chronic non-cancer pain were 606 of the 750 total cases
- The vast majority of overdoses happened in pts with no or lower dose opioids

12



### Dosage and Risk of Overdose from Opioids

"A Detailed Exploration Into the Association of Prescribed Opioid Dosage and Overdose Deaths Among Patients With Chronic Pain" Bohnert et al, Med Care 2016



2004-2009 study

- Nested case control design
- New starts of opioids for pts with chronic pain (excluding tramadol and buprenorphine)

Average opioid dosages
Cases (overdose deaths):
98.1 MEDD (SD 112.7)
Controls:

47.7 MEDD (SD 65.2)

- No clear cut-point in opioid dosage to distinguish between OD cases and controls.
- Median dosage for pts with OD was 60 mg; i.e. vast majority below 100 mg MEDD.

13



### Patient Risk Factors for Harm from Opioids

- **Psychiatric disorders**, including anxiety or depression.
- Personal or family history of substance use disorder.
- History of aberrant behavior/non-compliance.
- Age 65 or older.
- Young age (below 30).
- COPD or other underlying respiratory conditions.
- Renal or hepatic insufficiency.
- Pregnancy.

**Every patient is at risk** 



Obtaining overlapping prescriptions from multiple providers and pharmacies.



Having mental illness or a history of alcohol or other substance abuse.



Taking high daily dosages of prescription opioid pain relievers.





## The VA Opioid Safety Initiative (OSI)

- Opioid Safety Initiative (OSI) expanded nationally in FY 2013
- The OSI aims to reduce over-reliance on opioid analgesics for pain management and to promote safe and effective use of opioid therapy when clinically indicated.
- Comprehensive OSI strategy that includes education of providers and expanded access to non-pharmacological treatment options, in particular behavioral and complementary integrative health modalities.
- **OSI Dashboard** makes the totality of opioid use visible within VA and provides feedback to stakeholders at VA facilities regarding key parameters of opioid prescribing.



# The VA Opioid Safety Initiative (OSI) Timeline

#### **BIV** Initiative



· Launch of the Buprenorphine in VA (BIV) Initiative





#### OSI and AD

· Created standardized metrics for pain management therapies to pilot Opioid Safety Initiative (OSI)

Select regions pilot Academic Detailing (AD)


**OSI and PDSI** 



Psychotropic Drug Safety Initiative (PDSI) launched nationally

Academic Detailing

· Academic Detailing (AD) expands nationally to enhance Veteran outcomes by promoting evidencebased treatments



CARA requirements) VA-DoD develop Clinical Practice Guidelines (CPGs) on Opioid Therapy for Chronic Pain as well as Low Back Pain

Academic Detailing Opioid Use Disorder (OUD) Campaign

Teams, CPGs, and AD

2007

2009

2010

2012

2013

2014

2015

2016

2017

#### **OHRM Initiative and** PRIME Research

- Opioid High Risk Medication Initiative
- · Policy requiring access to medication for OUD
- · VA Pain Research. Informatics, Multimorbidities, and Education (PRIME) Center studies interaction between pain/associated chronic conditions and behavioral health factors



#### VA-DoD FIRST

VA-DoD develop clinical practice guideline (CPG) on Opioid Therapyin Chronic Pain (FIRST)



#### OSI Launch

Opioid Safety Initiative (OSI) launched in 5 regions



#### **Targeted intervention** and OEND

- Targeted interventions for opioid reduction in very high dose opioid patients
- Overdose Education and Naloxone Distribution (OEND) campaign



#### SUD and CARA

- VA-DoD develop clinical practice guideline (CPG) on Management of Substance Use Disorder (SUD)
- · Comprehensive Addiction and Recovery Act (CARA) implementation in VHA



# The Opioid Crisis - Nationally

- Presidential Memorandum: Addressing Prescription Drug Abuse and Heroin Use (Oct. 2015)
  - Training of all federal prescribers
  - Patients with OUD require access to addiction treatment incl. MAT
- CDC Opioid Prescribing Guidelines (March 2016)
  - Guidance for primary care providers
  - Recommendations includes non-opioid therapy as first line therapy for pain, limit opioid therapy to short duration/low dosage if possible, and specific dosage limits (50/90 mg MEDD)
- Comprehensive Addiction and Recovery Act (CARA) (July 2016)
  - Title IX: Jason Simcakoski Memorial Act with specific VHA mandates
- Presidential Opioid Commission Report (November 2017)
  - 56 recommendations



### Comprehensive Addiction and Recovery Act (CARA)

PUBLIC LAW 114-198-JULY 22, 2016

- Community interactions: 90-day regular meetings.
- Expanded VA Patient Advocacy program.
- VA/DoD Health Executive Committee Pain Management Workgroup.
- System-wide implementation of the Opioid Safety Initiative.
  - Opioid risk mitigation strategies: PDMP, UDS, informed consent.
  - Opioid Overdose Education and Naloxone Distribution (OEND)
- Dashboards to assess risk and monitoring opioid/pain care
- VA-DoD Clinical Practice Guideline for Opioid Therapy of Chronic Pain.
- Provider education in VA-DoD CPG and evidence based pain care
- Reporting of providers/facilities in conflict with care standards
- Expanded complementary and integrative health modalities.
- Full compliance with Stepped Care Model of Pain Management
- Pain Management Teams at all VA facilities.



#### VIEWPOINT

### Addressing the Opioid Epidemic in the United States

#### Lessons From the Department of Veterans Affairs

#### Walid F. Gellad, MD. MPH

Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System. Pittsburgh, Pennsylvania; and Center for Pharmaceutical Policy and Prescribing. University of Pittsburgh, Pittsburgh, Pennsylvania.

#### Chester B. Good, MD. MPH

stress

office:

tices,

opio

near

VA

tiv

Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System. Pittsburgh, Pennsylvania; and Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh, Pittsburgh, Pennsylvania.

#### David J. Shulkin, MD

Office of the Under Secretary for Health, US Department of Veterans Affairs, Washington, DC.

Over the past 15 years, more than 165 000 people in the United States have died from overdoses related to prescription opioids, 1 and millions more have suffered adverse consequences. 2,3 The misuse and abuse of prescription opioids have contributed to a precipitous increase in heroin and fentanyl overdoses.1

Patients treated in the health care system of the De-Coterans Affairs (VA) are part of this epipartment balf of veterans using the demic. C VA, com ties suc

pharmacists engage directly with opioid prescribers, similar to detailing by pharmaceutical representatives. The VA detailers use sophisticated dashboards with real-time prescriber-level data to engage clinicians in adopting best practices around opioid prescribing. This focus is not simply on reducing opioid medications, but rather on improving the safe use of opioids. Beyond detailing, the VA developed an overdose education and naloxone distribution system that has distributed tens of thousands of naloxone doses and developed stanpatient and provider education to comple-

Strategies to Address the Opioid Epidemic The VA has employed 4 broad strategies to address the opioid epidemic: education, pain management, risk mitigation, and addiction treatment (eTable in the Supple-

ment's data capabilities and

tives reduced the use of opioid medication proved the safety of opioid prescribing, while expanding alternative pain therapies (Figure). By mid-2016 compared with mid-2012, the number of veterans dispensed an opioid each quarter had decreased by 172 000, or about 25%. Moreover, there were 57 000 (47%) fewer patients receiving concomitant opioids and benzodiazepines and 22 000 (36%) fewer patients receiving daily opioid dosages of more than 100 morphinemilligram equivalents, both measures of potentially unsafe opioid use. Between 2010 and 2015, the rate of

macologic (eg, acup expanded mini-residency program consult capabilities for primary care clinicians to prove their management of pain.

#### Risk Mitigation

The VA implemented several strategies to support and track risk mitigation activities for opioid therapy (eTable in the Supplement). A key component of the Opioid



# **VA Opioid Data**


### **Department of Veterans Affairs Opioid Prescribing Data**

In keeping with the Department of Veterans Affairs' effort to be the most transparent agency in government, VA will begin posting information publicly on opioids dispensed from VA pharmacies, along with VA's strategies to prescribe these pain medications appropriately and safely.

The interactive map shows data over a five-year period (2012-2017) and does not include Veterans' personal information. The posted information shows opioid-dispensing rates for each facility and how much those rates have decreased over time. It is important to note that because the needs and conditions of Veterans may be different at each facility, the rates of the use of opioids may also be different for that reason, and cannot be compared directly.

The prescribing rate information will be updated semi-annually, on January 15 and July 15 of each year.

If you are having issues viewing the map please click here.





### VA Opioid Data Description and Example

The Opioid Safety Initiative (OSI) is the coordinating center for all of VA's efforts to promote safe prescribing practices and to address the broader opioid epidemic in the United States.

#### **Prescribing Rates**

Opioid prescribing rates are calculated by dividing the number of Veterans who received any opioid prescription by the total number of Veterans who received a prescription from that pharmacy within the specified time period.

#### **Percent Change**

The percent change represents the relative decrease (or increase) in opioid prescribing rates between 2012 and 2017. Overall, 99% of VA facilities have decreased prescribing rates since 2012.

#### Regional Non-VA Prescribing Rate

It is well-established that opioid prescribing rates and abuse vary across different parts of the country. Regional comparison categories were generated using publicly available data from the Centers for Medicare & Medicaid Services (CMS). CMS reports opioid prescribing rates by state, which are calculated by dividing the number of Medicare Part D claims for opioid medications by the total number of prescription claims.

Data for states are aggregated in to 5 groups by CMS. The "Low" Regional Non-VA comparison category represents the 40% of states with the lowest prescribing rates for Medicare beneficiaries. The "High" Regional Non-VA comparison category represents the 40% of states with the highest prescribing rates. The "Average" Regional Non-VA comparison category represents the 20% of states in the middle. The most current available comparison data is from 2015.

Search...

Facility	State	Rate in 2012	Rate in 2017	Percent Cha	Non-VA Rate
Louis Stokes Cleveland VA Medical Center	Ohio	5%	3%	-41%	Low
San Juan VA Medical Center	Puerto Rico	5%	3%	-34%	n/a
Edith Nourse Rogers Memorial Veterans' Hospital	Massachusetts	6%	4%	-34%	Low
East Orange VA Medical Center	New Jersey	6%	4%	-27%	Low
Manhattan VA Medical Center	New York	8%	4%	-49%	Low

https://www.data.va.gov/story/department-veterans-affairs-opioid-prescribing-data



### **OSI Parameters**


### OSI Dashboard (PBM) – quarterly updated

- 1. Opioid use overall, and Long-term opioid use
- 2. Opioid and Benzo co-prescribing
- 3. High dose >100 MEDD
- 4. UDS in Veterans on long-term opioid therapy within the last 12 months
- Report for provider specialty
- Report of all providers with high opioid prescribing / Outliers
- Informed consent policy issued 2014, for all pts on LTOT (90 d)
- PDMP checks policy issued 10/2016, at least annually, for > 5 d supply
- OEND Overdose Education and Naloxone Distribution
   Naloxone prescribed for all pts at risk, broad inclusion, no cost to Veteran
- Timely f/u with prescriber at least q3 months



### Veterans with Dispensed Opioid Medication

Q4 FY2012 to Q1 FY2018




Opioid patients (excludes tramadol)

Patients with opioid dispensed as percentage of all patients with pharmacy activity (excludes tramadol)



# Veterans with Opioid and Benzodiazepine Q4 FY2012 to Q1 FY2018




Opioid data include patients on tramadol




# Veterans on Long-Term Opioid Therapy

Q4 FY2012 to Q1 FY2018



Patients on opioid therapy (excluding tramadol) dispensed in the selected quarter and ≥90 days total cumulative supply of opioid medications in the last two quarters.


### Veterans Dispensed Greater Than Or Equal to 100 MEDD\*





# All Opioid and High Dose Opioid Therapy Q1 FY2003 to Q4 FY2017

#### **Veterans**




Q1 FY2003

Q1 FY2018



# High Dose Opioid Therapy Q1 FY2003 to Q1 FY2018





Q1 FY2003

Q1 FY2018



# Q1FY18: Top 10 Prescriber Specialties\*


Specialty	Count (#)
Physician**	10,562
Internal Medicine	4,145
Nurse Practitioner**	3,528
Primary Care	2,428
Physician Assistant**	2,049
Surgery	1,922
Dentist	1,509
Emergency Medicine	1,330
Podiatrist	678

<sup>\*</sup>Prescribers must have prescribed at least one opioid to be included in the count.

<sup>\*\*</sup>Specialty was not defined in administrative data.



# Average Daily Morphine Milligram Equivalent (MME)




CDC: <a href="https://www.cdc.gov/drugoverdose/pdf/pubs/2017-cdc-drug-surveillance-report.pdf">https://www.cdc.gov/drugoverdose/pdf/pubs/2017-cdc-drug-surveillance-report.pdf</a> <a href="https://www.cdc.gov/mmwr/volumes/66/wr/mm6626a4.htm#T1">https://www.cdc.gov/mmwr/volumes/66/wr/mm6626a4.htm#T1</a> down

VA: Pharmacy Benefits Management (PBM) Services

\*NOTE: VA data is Fiscal Year (October to September) and CDC is Calendar Year



# Opioid Utilization Rates, 2013-2016\*




CDC: https://www.cdc.gov/drugoverdose/pdf/pubs/2017-cdc-drug-surveillance-report.pdf

CMS: https://www.cms.gov/Medicare/HealthPlans/MedicareAdvtgSpecRateStats/Downloads/Announcement2018.pdf

VA: Pharmacy Benefits Management (PBM) Services.

\*NOTE: VA data is Fiscal Year (October to September) and CDC and CMS is Calendar Year

### Community Care/Choice: Veterans Dispensed an Opioid





## Community Care/Choice – OIG Report 2017

VA Office of Inspector General report on opioid prescribing, dated Aug 1, 2017 "Opioid Prescribing to High-Risk Veterans Receiving VA Purchased Care"

- Veterans receiving opioid prescriptions from VA-referred clinical settings may be at greater risk for overdose and other harm because medication information is not being consistently shared.
- "Healthcare providers serving veterans should be following consistent guidelines for prescribing opioids and sharing information that ensures quality care for high-risk veterans."
- OIG recommendations:
  - Non-VA providers to review the evidence-based guidelines for prescribing opioids in the OSI.
  - Include in care consults an updated list of the patient's medications and medical history.
  - Require non-VA providers to submit opioid prescriptions directly to VA pharmacies
  - If opioid prescribing in conflict with OSI guidelines: facility must taken action to ensure safety.
- Letter was sent out by facilities to all Non-VA providers by January 8, 2018.
- https://www.va.gov/oig/pubs/VAOIG-17-01846-316.pdf



### **Opioid Therapy Risk Mitigation**

- Patients receiving long-term opioid therapy should be monitored and reassessed at least every 3 months, with greater frequency based on risk.
- Always maintain vigilance for sedation, declining function, evidence of opioid use disorder or other opioid related harms.
- Each follow-up interaction with the patient is an opportunity to provide education about self-management strategies and the risks associated with opioid therapy while optimizing whole person approaches to pain care and treatment of comorbid health conditions.
- Essential components of Opioid Safety include:
  - (1) An informed consent for long-term opioid therapy.
  - (2) Prescription drug monitoring programs (PDMPs).
  - (3) Random urine drug testing.
  - (4) Overdose education, and naloxone distribution as appropriate (OEND).




### Informed Consent for Long-Term Opioid Therapy

- Informed consent (via I-Med) is required for all patients on Long Term Opioid Therapy (LTOT), defined as > 90 days (excluding patients enrolled in hospice, on opioids for cancer pain, when oral consent is sufficient)
- Opportunity to discuss risks of and alternatives to long-term opioid therapy with the veteran.
- Provides some protection to provider and facility in case of harm to the patient related to opioid therapy.
- Brochure "Taking Opioids Responsibly" should given to the patient.
- Currently being updated.

### January 05, 2018 report:

National Score: 89.7%





### Prescription Drug Monitoring Programs (PDMP)



As of January 2018, 48 states and the District of Columbia are activated for PDMP data transmission.


States share data through <a href="PMP">PMP</a>
<a href="InterConnect">InterConnect</a>

- Veterans in VHA: 23.9% received controlled substance, and 12% opioids
- From Q3 FY 2013 to Q4 FY 2017, VA providers documented > 2.3 million queries
- Long-Term Opioid Therapy Patients with a PDMP within the last 365 days: 70.2% (Jan. 2017)
- VHA Directive 1306, Querying State Prescription Drug Monitoring Programs (PMDP). Oct. 19, 2016

MO just recently established a statewide PDMP by executive order. NE's program has transitioned to Appriss AWARXE and work is underway to initiate transmissions; state working to implement FIPS 140-2 cryptography required for federal data sharing. VA-NSOC requires specific security documentation in order to open the firewall for outbound transmissions.



# National: State Prescription Drug Monitoring Program (PDMP) Queries and the Number of Veterans Dispensed a Controlled Substance Prescription\*



\*Queries are underestimated because documentation was not standardized system-wide prior to publication of VHA Directive 1306



Source: Pharmacy Benefits Management (PBM) Services



## Overdose Education and Naloxone Distribution - OEND

## Overdose Education (OE)

Education on how to prevent, recognize, and respond to an opioid overdose.

## Naloxone Distribution (ND)

- FDA approved as naloxone autoinjector and nasal spray.
- Dispense and train patient and caregiver/family.
- Target patient populations: OUD, and prescribed opioids.
- Highly successful: > 100,000 kits dispensed to > 70,000 Veterans
- From May 2014 to Jan 2016, 172 overdose reversals documented
- Offer naloxone when factors that increase risk for opioid overdose are present: h/o overdose, h/o SUD, higher opioid dosages (≥50 MMED), or concurrent benzodiazepine use.
- No cost to patients (elimination of copays for naloxone and training, as per CARA)



# **Education: Academic Detailing**

### **Academic Detailing**


A III VA Academic

Detailing Service

- In-person educational outreach
  - Information is provided *interactively* so the academic detailer can:
    - Understand where the provider is coming from in terms of knowledge, attitudes, and personal motivations for practice
    - Modify the interaction to meet the needs of the provider
    - Engage the provider by acknowledging their expertise and learning together rather than teaching
- Uses balanced evidence-based information and tools
- Delivered by a healthcare professional specially skilled in empathic persuasive communication
- Over time, the educator and provider develop a trusted and useful relationship
- Multiple campaigns incl. Pain Management, Opioid Safety Initiative, Opioid Use Disorder (OUD), Insomnia; Psychotropic Drug Safety Initiative (PDSI), incl. benzodiazepines.
- http://www.pbm.va.gov/PBM/academicdetailingservicehome.asp




## Academic Detailing: Impact on Naloxone Prescribing





## Academic Detailing: Impact on Veterans > 100 MEDD





## Self Care/Active non-Pharmacologic Therapies **SOTA 2016**



Massage

Acupuncture

**Manipulation** 

Cognitive Behavioral

Therapy (CFT)

Yoga

Mindfulness Based Stress

Reduction (MSBR)

**Acceptance & Commitment** 

Therapy (ACT)

Tai Chi

**Aerobic Exercise** 

**Coordination**/

Stabilisation Exercise

**Resistance Exercise** 

**Behavioral/ Psychological Therapies** 

Exercise/ Movement **Therapies** 




## Whole Health System Flagship Sites





# Stratification Tool for Opioid Risk Monitoring – STORM

- Predicts individual risk of overdose or suicide-related health events or death in the next year
- For patients on opioids and when considering opioid therapy.
- Identifies patients at-risk for opioid overdose-/suicide-related adverse events.
- Provides patient-centered opioid risk mitigation strategies.
- Risk score is designed to support treatment planning. The goal should be to design a treatment plan that addresses risk factors and is appropriate for the patients risk level.
- <a href="https://spsites.cdw.va.gov/sites/OMHO">https://spsites.cdw.va.gov/sites/OMHO</a> PsychPharm/Pages/Real-Time-STORM-Dashboard.aspx





## Opioid Therapy Risk Report – OTRR


- Tool optimized for PACT: review their panel for all patients on long-term opioids
- Included in CPRS under Tools → Primary Care Almanac.
- Veteran lookup by SSN
- Multitude of factors that potentially increase risk incl. MH diagnoses
- Opioid risk mitigation parameters including last PDMP check
- Updated nightly
- Individual report includes Visual display
  - Opioid dosage
  - Pain score (severity)
- LTOT definition: opioid dispensed in the last 90 days and total days supply ≥ 90 days in the past 180 days





# VA/DoD Opioid Therapy CPG





The guideline describes the critical decision points in the Management of Opioid Therapy (OT) for Chronic Pain and provides clear and comprehensive evidence based recommendations incorporating current information and practices for practitioners throughout the DoD and VA Health Care systems. The workgroup consensus statements are provided to minimize harm and increase patient safety in patients requiring opioid therapy.

**Disclaimer:** This Clinical Practice Guideline is intended for use only as a tool to assist a clinician/healthcare professional and should not be used to replace clinical judgment.

#### About the CPG

The guideline is formatted as a single algorithm with annotations.

Questions about the OT Guideline

# OT Full Guideline (2017) OT Provider Summary (2017) OT Pocket Card (2017)

Patient-Provider Tools	
OT Patient Summary (2017)	
Managing Side Effects Fact Sheet (2017)	1
Patient Information Guide (2017)	3


Related Guidelines
Substance Use Disorder
(SUD)

http://www.healthquality.va.gov/guidelines/Pain/cot/



## VA/DoD Clinical Practice Guideline: Opioid Therapy


- "We recommend against initiation of long-term opioid therapy".
  "We recommend alternatives to opioid therapy such as self-management strategies and other non-pharmacological treatments. When pharmacologic therapies are used, we recommend non-opioids over opioids".
- Recommendation against opioid therapy in patients < 30 years of age, in patients with active substance use disorder, and in combination with benzos.
- Recommendation for risk mitigation strategies, including urine drug testing,
   PDMP, overdose education, naloxone distribution
- If prescribing opioids: short duration and lowest dosage
- No dosage is safe; Strong rec against of opioids to > 90 MEDD.
- Opioid dosage reduction should be individualized to patient.
   Avoid sudden reductions; <u>taper slowly</u> if opioid risk>benefit
- Suicide prevention in pain patients
- Use multimodal pain care
- Acute pain: use alternatives to opioids; if opioids  $\leq$  3-5 days
- For OUD, offer medication assisted treatment. <a href="https://www.healthquality.va.gov/guidelines/Pain/cot/">https://www.healthquality.va.gov/guidelines/Pain/cot/</a>





# Reduction in Opioid Prescribing in VHA

Impact of the Opioid Safety Initiative on opioid related prescribing in veterans



Lin et al, Pain 2018

- Interrupted time series analyses
- October 2012 to September 2014

High-dosage opioid >100 MME:

High dosage opioid > 200 MME:

Benzodiazepine coprescribing:

331 per month reduction due to OSI

164 per month reduction due to OSI


781 per month reduction due to OSI



# Reduction in Opioid Prescribing in VHA

Decline in Prescription Opioids Attributable to Decreases in Long-Term Use: A Retrospective Study in the Veterans Health Administration 2010–2016

Hadlandsmyth et al, J Gen Intern Med 2018




- 83% of decline in opioid scripts due to decreases in LOT.
- 90% of reduction from fewer new LOT prescription fills.
- < 10% from increases in cessation of existing LOT users



# Reduction in Opioid Prescribing in VHA

Decline in Prescription Opioids Attributable to Decreases in Long-Term Use: A Retrospective Study in the Veterans Health Administration 2010–2016

Hadlandsmyth et al, J Gen Intern Med 2018



- 83% of decline in opioid scripts due to decreases in LOT.
- 90% of reduction from fewer new LOT prescription fills.
- <10% of reduction from increases in cessation of existing LOT users</li>



# **Opioid Tapering Considerations**

- Several factors go into the speed of taper selected:
  - Slower, more gradual tapers are often the most tolerable and can be completed over a several months to years based on the opioid dose
  - The longer the duration of the opioid therapy, the longer the taper
  - CDC: "... patients tapering opioids after taking them for years might require very slow opioid tapers as well as pauses in the taper to allow gradual accommodation to lower opioid dosages."
- Most commonly, tapering will involve dose reduction of 5-20% every 4 weeks.
- More rapid tapers may be required in situations where the risks of continuing the opioid outweigh the risks of a rapid taper.
- SUDDEN interruption of opioid prescribing must be avoided for opioid dependent patients with few exceptions (safety issues, diversion, etc.)
- F/u is recommended within 1 to 4 weeks after dosage adjustment.




# Approaching Opioid Tapering.

- Integrated approach with patient buy-in and active participation leads to improved pain control and enhanced quality of life.
- Goal is to improve function and long-term outcome while reducing risk.
- Provider approach: empathetic, personalized, building trust.
- Patients are often scared about opioid dosage reduction, and some are desperate, especially if they have features of opioid use disorder.
- Expectations should be clear and reasonable/achievable. The patient needs a clear plan that appears manageable and helps avoid or minimize fear or anxiety.
- Close collaboration with mental health providers including addiction medicine is recommended for many patients - evaluation for OUD and, if present, referral to Medication-Assisted Treatment is usually indicated.
- Caution: Involuntary tapers may carry significantly greater risk than voluntary tapers, and interfere with collaborative provider/patient relationship and shared decision making.



## SUD and OUD in VHA

- Prevalence of SUD in VHA
  - 10% of Veterans (600,000 in FY 2015)
  - AUD >> other SUD
- "Diagnosed" OUD
  - 1.1% of Veterans (FY 2015)
  - About 60,000 Veterans total
  - 23,000 Veterans on MAT (2016)



- What is the Prevalence of OUD in Veterans on long-term opioids?
  - Estimate of 25 to 40% of LOT patients?
  - How many truly have OUD? 10,000 to 100,000 Veterans?
  - How many need addiction medicine? MAT?



# Stepped Care Model for Pain Management

VA-DoD Stepped Pain Care

**Complexity** 

#### RISK

Comorbidities

#### Tertiary, Interdisciplinary Pain Centers

Advanced pain medicine diagnostics & interventions;

**CARF** accredited pain rehabilitation

# **Treatment Refractory**

#### **Secondary Consultation**

Multidisciplinary Pain Medicine Specialty Teams; Rehabilitation Medicine; Behavioral Pain Management; Mental Health/SUD Programs

#### **STEP**

STEP

3

2

#### Patient Aligned Care Team (PACT) in Primary Care

Routine screening for presence & severity of pain; Assessment and management of common pain conditions; Support from MH-PC Integration; OEF/OIF, &

Post-Deployment Teams; Expanded care management; Pharmacy Pain Care Clinics; Pain Schools; CAM integration

#### STEP

1

#### **Patient/Family Education and Self Care**

Understand BPS model; Nutrition/weight mgmt, exercise/conditioning, & sufficient sleep; mindfulness meditation/relaxation techniques; engagement in meaningful activities; family & social support; safe environment/surroundings

1



## **CARA Pain Teams**

- CARA mandates designated Pain Management Teams at all VA facilities
- Developed the Pain Management Team standards and provided the information to directors regarding reporting requirements.
- Veterans must have timely access to **specific components of pain care** that are available system-wide
- Coordination between the different clinical areas is essential to promote efficient use of resources and smooth transition of the Veteran between the care areas.
- Facility with higher complexity may be tasked to provide services to lower resourced facilities via tele-health/VA-ECHO, as VISN-supported hubs.
- Field Data call for the collection of the Facility Director Reports on Pain Management Teams is ongoing.




# Pain Management Teams - Requirements

### The functions of the Pain Management Team (PMT) include:

- Evaluation and follow-up of pts with complex pain conditions
- Medication management and actual prescribing of pain meds, as needed.
- **OSI Reviews**: Review of patients with high risk opioid prescriptions with provision of recommendations to clinical providers
- At a minimum, the composition of the PMT must include:
  - Medical Provider with Pain Expertise
  - Addiction Medicine expertise to provide evaluation for Opioid Use Disorder (OUD) and access to Medication-Assisted Treatment (MAT)
  - **Behavioral Medicine** with availability of at least one evidence-based behavioral therapy.
  - Rehabilitation Medicine discipline.




# The PCP and the OSI....?



**Caution: Perceived Burden on the PCP** 



# Integrated Pain Care in VHA



Collaborative Care that centers around the patient and supports the PCP/PACT team



# STORM Risk Factors for Overdose/Suicide

"Development and Applications of the Veterans Health Administration's Stratification Tool for Opioid Risk Mitigation (STORM) to Improve Opioid Safety and Prevent Overdose and Suicide"

Oliva et al, Psych Serv 2016


Variable	<b>Odds Ratio</b>	
Age (years)		
<=30	3.7	
31–50	3.5	
51–65	2.3	
>=66 (reference)	1.0	
Previous treatment risk indicators		
Previous overdose/suicide	23.1	
Detoxification	18.5	
Inpatient MH treatment	16.6	
ER visit	3.4	

Variable	<b>Odds Ratio</b>	
Prescription related		
Opioid type, tramadol=referenc	e	
Tier 1 (long acting)	1.5	
Tier 2 (chronic, short acting)	1.1	
Tier 3 (acute, short acting)	1.1	
Coprescription with sedatives	1.4	
# of classes other sedating		
1	2.1	
2	3.6	
3	6.1	

59



# STORM Risk Factors for Overdose/Suicide



Variable	<b>Odds Ratio</b>	
Medical comorbidities		
AIDS	2.2	
Liver disease	2.2	
Other neurological disorder	2.2	
Electrolyte disorders	2.0	
Weight loss	1.9	
Coagulopathy	1.4	
Paralysis	1.4	
Chronic obstructive pulmonary	1.3	
Metastatic cancer	1.3	
Pulmonary circulation disorder	1.3	
Sleep apnea	1.2	
Deficiency anemia	1.2	

Oliva et al, Psych Serv 2016

60



# Opioids and Suicide



## Opioid dose and risk of suicide

Mark A. Ilgen<sup>a,b,\*</sup>, Amy S.B. Bohnert<sup>a,b</sup>, Dara Ganoczy<sup>a</sup>, Matthew J. Bair<sup>c,d</sup>, John F. McCarthy<sup>a,b</sup>, Frederic C. Blow<sup>a,b</sup>

- VA patients with chronic pain receiving opioids in FY 2004-2005 (N=123,946).
- 2,601 patients died by suicide before the end of 2009.
- Controlling for demographic and clinical characteristics, higher prescribed opioid doses were associated with elevated suicide risk.
  - Compared with those receiving ≤20 mg/d
  - 20 to <50 mg/d HR 1.48 (95% CI, 1.25-1.75)
  - 50 to <100 mg/d HR 1.69 (95% CI, 1.33-2.14)
  - 100+ mg/d HR 2.15 (95% CI, 1.64-2.81)
- Veterans receiving the highest doses of opioid painkillers were more than twice as likely to die by suicide.
- The researchers could not tell, however, whether there was a direct causal link between the pain medications and suicide risk.
- High doses may be a marker for other factors that drive suicide, including unresolved severe chronic pain.



# What is the Impact of Opioid Safety Policies?

# Mandatory Provider Review And Pain Clinic Laws Reduce The Amounts Of Opioids Prescribed And Overdose Death Rates

Dowell et al, Health Affairs 2016

- IMS Health's National Prescription Audit and government mortality data to examine the effect of these policies on opioid prescribing and on prescription opioid and heroin overdose death rates in the United States during 2006 – 13.
- Combined implementation of mandated provider review of state-run prescription drug monitoring program data and pain clinic laws reduced opioid amounts prescribed by 8 percent and prescription opioid overdose death rates by 12 percent.
- We observed relatively large but statistically insignificant reductions in heroin overdose death rates after implementation of these policies.



# What is the Impact of Opioid Safety Policies?


# Patient Outcomes in Dose Reduction or Discontinuation of Long-Term Opioid Therapy: A Systematic Review

Frank et al, Ann Intern Med 2017

- 67 studies (11 randomized trials and 56 observational studies) examining 8 intervention categories, including interdisciplinary pain programs, buprenorphine-assisted dose reduction, and behavioral interventions, were found.
- Study quality good for 3 studies, fair for 13 studies, poor for 51 studies.
- Among 40 studies examining patient outcomes after dose reduction (very low overall quality of evidence), improvement was reported in pain severity (8 of 8 fair-quality studies), function (5 of 5 fair-quality studies), and quality of life (3 of 3 fair-quality studies).
- Conclusion: Very low quality evidence suggests that several types of interventions may be effective to reduce or discontinue LTOT and that pain, function, and quality of life may improve with opioid reduction.



# The Opioid Crisis is Continuing in the US



- Opioid overdose deaths continue to climb
- Large number of the population that has been exposed to opioids
- Availability of illicit opioids
- Lethality of illicit substances

- High rate of OUD/complex dependence
- OUD/Addiction continues to be stigmatized
- Lack of resources for OUD care and challenges to enter treatment program
- High relapse/failure rate in patients with OUD, esp. if not on MAT
- Fragmented, poorly integrated care



# Opioid Risk and STORM data

- Veterans on opioid medication in FY 2010 who had their opioid therapy discontinued by FY 2011 were compared with Veterans who stayed on opioids.
- Groups did not differ in opioid overdose rates.
- Evidence that Veterans with opioid discontinuations had elevated suicide rates compared to Veterans who remained on opioid therapy.
- Patients with MH, and in particular SUD comorbidities, are highly vulnerable,
   especially if they were on high dose opioid medication
- Veterans with opioid discontinuation may have greater behavioral or medical risks for OD/Suicide than patients remaining on opioid therapy.
- High risk on the STORM dashboard suggests the need for active risk management, such as close f/u and case management/care coordination.
- Interdisciplinary OSI Reviews using STORM data can identify patients at very high risk for OD/Suicide. These care reviews may allow the interdisciplinary OSI review team to focus resources on such patients including case management.
- MH and Addiction medicine providers must be part of the OSI review teams to maximize benefit and allow for care coordination.



# Opioids and Mental Health

The missing 'P' in pain management: how the current opioid epidemic highlights the need for psychiatric services in chronic pain care \_

Howe CQ, Sullivan MD

Gen Hosp Psychiatry, 2014;36(1):99-104

"The opioid epidemic thus reflects a serious unmet need for better recognition and treatment of common mental health problems in patients with chronic pain. Psychiatry is the missing P in chronic pain care"

Rates and Correlates of Pain Specialty Clinic Use Nationally in the Veterans Health Administration.

Arout CA, Sofuoglu M, Rosenheck RA

Pain Med, 2017; 18(4):702-710

"Patients attending pain specialty clinics have more difficult-to-treat pain conditions and comorbid, psychiatric disorders (...), use more outpatient services, and receive a greater number of opioid prescriptions. These data support the inclusion of mental health care in the specialized treatment of chronic pain."



# S.T.O.P. P.A.I.N. Toolbox

#### Toolbox available to the public on our website:

https://www.va.gov/PAINMANAGEMENT/Opioid Safety Initiative OSI.asp

S	Stepped care model
T	Treatment alternatives/ complementary and integrative care
	Ongoing monitoring of usage
P	Practice guidelines
P	Prescription monitoring
A	Academic detailing
	Informed consent for patients
N	Naloxone distribution



# Summary – VHA OSI and Pain Teams

- 1. In accordance with CARA, VHA is reducing reliance on opioid medication for chronic pain management, providing safer prescribing and monitoring practices, and Veteran-centric, biopsychosocial pain care.
- 2. The majority of Veterans with chronic pain conditions receive their care from Primary Care. Well-trained PACT teams must be supported with access to patient education/self-care programs and non-pharmacological pain treatment modalities. The PACT Pain Roadmap is a valuable tool.
- 3. Veterans with high impact/severe chronic pain benefit from biopsychosocial pain care by an **interdisciplinary Pain Team that works collaboratively** with Primary Care. Pain Management teams at all facilities to support PACT are legislatively mandated by CARA.
- **4. Telehealth, E-consultation, VA-ECHO** are tools to maximize resources.
- 5. MH comorbidities are common in patients with chronic pain. **Integration of MH providers and access to OUD treatment** within Pain teams and Primary care are essential for success.
- **6. Centralized pain care reviews** by interdisciplinary pain teams allow targeted interventions to minimize risk and optimize outcomes.



## Thank You

#### **Contact information:**

friedhelm.sandbrink@va.gov

Phone 202-745-8145



- VACO, VISN and Facility leadership
- VISN POCs and all facility POCs for PAIN
- OSI POCs and the OSI review committees
- Pain research community
- Pain Medicine Specialty Teams
- Pain Psychologists
- PACT Pain Champions, Primary Care
- PBM/Pharmacy
- Academic Detailing
- Mental Health
- Suicide Prevention
- Addiction Medicine
- Nursing Service
- Rehabilitation Medicine
- Integrative Health, IHCC and OPCC
- EES, Ethics
- Connected Care/Telehealth

www.va.gov/painmanagement

The Veterans and their families